Difference between revisions of "Team:NJU-China"

m
m
Line 138: Line 138:
 
             <div class="section">
 
             <div class="section">
 
                 <div class="row">
 
                 <div class="row">
                     <div class="card blue-grey lighten-1 z-depth-3">
+
                     <div class="card blue-grey darken-1 z-depth-3">
 
                         <div class="card-content white-text">
 
                         <div class="card-content white-text">
 
                             <span class="card-title">
 
                             <span class="card-title">
Line 144: Line 144:
 
                             </span>
 
                             </span>
 
                             <div class="card-action">
 
                             <div class="card-action">
                                 <a class="waves-effect waves-light btn"><i class="material-icons left">vpn_key</i>Keyword 1</a>
+
                                 <a class="waves-effect waves-dark btn red darken-1"><i class="material-icons left">vpn_key</i>Keyword 1</a>
                                 <a class="waves-effect waves-light btn"><i class="material-icons left">vpn_key</i>Keyword 2</a>
+
                                 <a class="waves-effect waves-dark btn red darken-1"><i class="material-icons left">vpn_key</i>Keyword 2</a>
                                 <a class="waves-effect waves-light btn"><i class="material-icons left">vpn_key</i>Keyword 3</a>
+
                                 <a class="waves-effect waves-dark btn red darken-1"><i class="material-icons left">vpn_key</i>Keyword 3</a>
 
                             </div>
 
                             </div>
 
                             <p>Cancers, as the most frightening death threats, are aggressive and malignant. However, a perfect treatment of cancer has not appeared so far. The goal of our project is to develop a strategy to treat cancers, with building a transplantable drug system targeting a specific molecule that functions in cancer. We packed siRNA into exosomes (nano-sized vesicles secreted by human cells) to deliver our drug into certain part of a patient's body. Then we modified our exosome with iRGD to act as integrin-specific targeting tool. Our validation experiments will be carried out at the level of cells and animals to prove both the targeting and silencing function of this drug. Eventually, we expect to see a specific accumulation of the siRNA in the mice’s tumor tissues and the decreased expression of the oncogenes at the transcription level. This project may provide new insights into future treatment of cancer.</p>
 
                             <p>Cancers, as the most frightening death threats, are aggressive and malignant. However, a perfect treatment of cancer has not appeared so far. The goal of our project is to develop a strategy to treat cancers, with building a transplantable drug system targeting a specific molecule that functions in cancer. We packed siRNA into exosomes (nano-sized vesicles secreted by human cells) to deliver our drug into certain part of a patient's body. Then we modified our exosome with iRGD to act as integrin-specific targeting tool. Our validation experiments will be carried out at the level of cells and animals to prove both the targeting and silencing function of this drug. Eventually, we expect to see a specific accumulation of the siRNA in the mice’s tumor tissues and the decreased expression of the oncogenes at the transcription level. This project may provide new insights into future treatment of cancer.</p>

Revision as of 09:24, 13 October 2016

Say goodbye to Mr. Tumor: targeted therapy for cancer based on siRNA-exosome drug system

Cancers, as the most frightening death threats, are aggressive and malignant. However, a perfect treatment of cancer has not appeared so far. The goal of our project is to develop a strategy to treat cancers, with building a transplantable drug system targeting a specific molecule that functions in cancer. We packed siRNA into exosomes (nano-sized vesicles secreted by human cells) to deliver our drug into certain part of a patient's body. Then we modified our exosome with iRGD to act as integrin-specific targeting tool. Our validation experiments will be carried out at the level of cells and animals to prove both the targeting and silencing function of this drug. Eventually, we expect to see a specific accumulation of the siRNA in the mice’s tumor tissues and the decreased expression of the oncogenes at the transcription level. This project may provide new insights into future treatment of cancer.

Acknowledgement

We would like to express our most sincere gratitude to every person and institute that helped us during this whole project.

Links